Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Keri R. Maher"'
Autor:
Ian M. Bouligny, Graeme Murray, Michael Doyel, Tilak Patel, Josh Boron, Valerie Tran, Juhi Gor, Yiwei Hang, Yanal Alnimer, Kyle Zacholski, Chad Venn, Nolan A. Wages, Steven Grant, Keri R. Maher
Publikováno v:
eJHaem, Vol 4, Iss 2, Pp 381-392 (2023)
Abstract Treatment paradigms for acute myeloid leukemia (AML) have evolved at a rapid pace in recent years. The combination of venetoclax with a hypomethylating agent prolonged survival in clinical trials when compared to hypomethylating agent monoth
Externí odkaz:
https://doaj.org/article/4cc2b60d1da740f8a15604fb058c1e94
Publikováno v:
Journal of Radiological Protection. 41:R176-R188
Ionising radiation impacts many organ systems, each of which comprises a level of immunity to infectious disease. Bone marrow toxicity after radiation results in a predisposition to leukopenia and subsequent susceptibility to bacterial, viral, and fu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9aa9a4fdd0e09d3dc2a9f639a71e75e4
https://doi.org/10.1088/1361-6498/ac14d3
https://doi.org/10.1088/1361-6498/ac14d3
Publikováno v:
Blood Reviews. 57:100996
Acute myeloid leukemia (AML) is a heterogeneous hematopoietic neoplasm which results in clonal proliferation of abnormally differentiated hematopoietic cells. In this review, mechanisms contributing to myeloid leukemogenesis are summarized, highlight
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a5a0dda886ec92fd0cbcd282a2f7c17
https://doi.org/10.1016/j.blre.2022.100996
https://doi.org/10.1016/j.blre.2022.100996
Autor:
Keri R. Maher, Ian M. Bouligny
Publikováno v:
Blood. 138:2335-2335
Background: The addition of venetoclax to a hypomethylating agent (HMA) backbone has been shown to augment responses when compared to HMA monotherapy or to low-dose cytarabine in the treatment of acute myeloid leukemia (AML). The aim of this retrospe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f64a55726a1fd0ecb7acb12f9d6b27ba
https://doi.org/10.1182/blood-2021-153738
https://doi.org/10.1182/blood-2021-153738
Autor:
Keri R. Maher, Ian M. Bouligny
Publikováno v:
Blood. 138:1987-1987
Background: Acute myeloid leukemia (AML) is an aggressive bone marrow cancer affecting 20,000 adults in the United States yearly. Five-year relative survival remains poor at 29.5%, though this has been steadily increasing. There are no known differen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3197d93df7f155f094a098c24e1d9665
https://doi.org/10.1182/blood-2021-153642
https://doi.org/10.1182/blood-2021-153642
Autor:
Keri R. Maher, Ian M. Bouligny
Publikováno v:
Blood. 138:4424-4424
Background: Sequencing and selection of salvage regimens for acute myeloid leukemia (AML) remains unclear. Venetoclax augmentation of a hypomethylating agent (HMA) backbone has joined the salvage armamentarium following impressive performance in the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aa6cdeb6ab4c2df7101c7477e21459a0
https://doi.org/10.1182/blood-2021-153690
https://doi.org/10.1182/blood-2021-153690
Autor:
Ian M. Bouligny, Keri R. Maher
Publikováno v:
Blood. 138:4452-4452
Background: Clonal diversity and evolution in acute myeloid leukemia (AML) are consequences of disease progression and play a pivotal role in the development of drug resistance and refractoriness to therapy. Much work has been done with characterizin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d32840bc10755202cced0f358970546a
https://doi.org/10.1182/blood-2021-153194
https://doi.org/10.1182/blood-2021-153194
Autor:
Keri R. Maher, Ian M. Bouligny
Publikováno v:
Blood. 138:4386-4386
Background: The optimal induction strategy for patients with acute myeloid leukemia (AML) older than 65 years remains unknown. The use of lower intensity therapies in this population has become routine. The inclusion of venetoclax to intensify a hypo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::88d2cf7351c6848d6256185d6ff91389
https://doi.org/10.1182/blood-2021-153526
https://doi.org/10.1182/blood-2021-153526
Autor:
Keri R. Maher, Ian M. Bouligny
Publikováno v:
Blood. 138:2336-2336
Background: Acute myeloid leukemia (AML) is an aggressive hematologic malignancy with a poor prognosis in the adult population, despite recent advancements in treatment paradigm. Induction with the liposomal formulation of cytarabine and daunorubicin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ec27c552193246b7fad3e820b6afdd73
https://doi.org/10.1182/blood-2021-153918
https://doi.org/10.1182/blood-2021-153918
Cellular transplant therapies for globoid cell leukodystrophy: Preclinical and clinical observations
Autor:
Keri R, Maher, Andrew M, Yeager
Publikováno v:
Journal of neuroscience research. 94(11)
Globoid cell leukodystrophy (GLD) is a progressive neurodegenerative disorder caused by the deficiency of galactocerebrosidase (GALC), resulting in accumulation of toxic metabolites in neural tissues. Clinically variable based on age of onset, infant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::738e78bac09c5f2ebf8bedd8bca313bb
https://pubmed.ncbi.nlm.nih.gov/27638602
https://pubmed.ncbi.nlm.nih.gov/27638602